Aimee M. Crago, MD, PhD

I am the author of numerous articles, chapters, and reviews on the management and biology of soft tissue sarcomas. In addition to my clinical practice, I coordinate an active research effort, examining the genetic alterations that lead to the development of these tumors. My work has been funded by the Kristen Ann Carr Foundation, Cycle for Survival, the American Society of Clinical Oncology, and the American College of Surgeons. Much of my research examines the DNA of soft tissue sarcoma and how we can use information on DNA changes in sarcoma to develop better therapies for cancer care. My findings have increased knowledge of the central pathways that contribute to liposarcoma initiation and to the development of aggressive disease. I have helped to identify novel biomarkers that may help predict which patients can benefit from CDK4 inhibitors, which are experimental drugs currently being studied in clinical trials at our institution. 

I also have a special interest in desmoid tumors. Working with members of the French Sarcoma Group, I have defined risk factors that predict whether a patient's desmoid is likely to come back after surgery. These findings allow us to define which patients are best managed with surgery versus drug therapy or monitoring without immediate treatment. Refining current treatment practices will help us to prevent many of the complications traditionally resulting from desmoid tumors. Along with this clinical research, I am actively examining the genomics of desmoid fibromatosis. Working with colleagues at the Broad Institute of the Massachusetts Institute of Technology and Harvard, I have identified changes in DNA that correlate with the formation of desmoids (and also with solitary fibrous tumors). We are hopeful that an in-depth analysis of these changes will lead to new treatments for patients with these diseases.